Analysts Upgrade DexCom (DXCM) to “Outperform,” Driving Share Recovery
Alpha Wealth Funds, LLC, an investment management company, released its Q1 2025 letter for the “Insiders Fund”. A copy of the letter can be downloaded here.
Dexcom Inc (DXCM)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 2,545,103 | $159,832,468 | +101% | 0.09% |
| 2. | AQR Capital Management Cliff Asness | 2,173,497 | $136,495,623 | -30% | 0.06% |
| 3. | Citadel Investment Group Ken Griffin | 2,091,872 | $131,369,562 | +2308% | 0.02% |
| 4. | Adage Capital Management Phill Gross And Robert Atchinson | 1,666,408 | $104,650,422 | +5% | 0.16% |
| 5. | Millennium Management Israel Englander | 1,622,204 | $101,874,411 | +3% | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $55.43 | 2,500 | $138,563.00 | 331,697 | 2025-11-10 | Filing | |
| $54.98 | 15,700 | $863,138.90 | 329,197 | 2025-11-10 | Filing | |
| $50.01 | 25,000 | $1,250,250.00 | 58,502 | 2017-11-07 | Filing | |
| $49.61 | 10,000 | $496,100.00 | 33,502 | 2017-11-06 | Filing | |
| $15.50 | 70,000 | $1,085,000.00 | 121,975 | 2013-03-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $59.91 | 1,700 | $101,847.00 | 109,504 | 2026-05-15 | Filing | |
| $60.01 | 1,012 | $60,730.12 | 25,007 | 2026-05-12 | Filing | |
| $63.04 | 1,700 | $107,168.00 | 111,204 | 2026-04-15 | Filing | |
| $64.85 | 1,700 | $110,245.00 | 112,904 | 2026-03-16 | Filing | |
| $68.01 | 1,012 | $68,826.12 | 26,019 | 2026-02-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 38,964,371 | $2,446,962,501 | 0.04% | |
| 2. | 25,020,961 | $1,571,316,351 | 0.03% | |
| 3. | 19,219,953 | $1,207,013,048 | 0.06% | |
| 4. | 17,934,847 | $1,126,308,392 | 0.04% | |
| 5. | 15,599,525 | $979,650,170 | 1% |
News See All
10 Stocks Dominating With Powerful Gains
The stocks defied a lackluster performance on Wall Street, with all three major indices ending in the red.
12 Best Growth Stocks to Invest In for the Next 2 Years
On May 1, Chris Harvey, CIBC, joined CNBC's 'Closing Bell' to discuss the surprising speed of the market's recovery, noting that while he expected equities to rise and saw a buying opportunity, the move...
DexCom, Inc. (NASDAQ:DXCM) Q1 2026 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the DexCom, Inc. First Quarter 2026 Earnings Release Conference Call. My name is Abby, and I will be your operator for today's call.
BTIG Remains Bullish on DexCom, Inc. (DXCM)
DexCom, Inc. (NASDAQ:DXCM) is one of the best medical device stocks to invest in right now. BTIG cut the price target on DexCom, Inc.
10 Best Medical Device Stocks to Invest In Right Now
On April 27, Tom Lee, Fundstrat Capital Chief Investment Officer and Bitmine Immersion Technologies Chairman, appeared on CNBC's ‘Power Lunch’ to discuss the outlook for equity markets.
Is DexCom, Inc. (DXCM) A Good Stock To Buy Now?
Is DXCM a good stock to buy? We came across a bullish thesis on DexCom, Inc. on Part-Time Compounder’s Substack by Francesco Ferrari.
Aristotle Growth Equity Fund Bets on DexCom (DXCM) Due to Its Expanding CGM Market Leadership
Aristotle Funds, an investment advisor, released its “Growth Equity Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S.
Mizuho Raises DexCom (DXCM) Price Target to $90 from $78 After Earnings Beat
On February 13, Mizuho analyst Anthony Petrone raised the price target on DexCom, Inc.
DexCom, Inc. (DXCM) Continues to Focus on Glucose Sensors Leadership
Plovanic noted that fourth-quarter results and 2026 outlook met expectations, as the company’s strategy remains unchanged. Management continues to focus on product refinements across the U.S.
Hedge Fund Resource Center